https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0343183
Gemini Summary:
This study, published in PLOS ONE by Clement Torrent and colleagues, investigates whether long-term, low-dose rapamycin usage causes widespread immunosuppression or serves as a targeted anti-aging intervention.
While rapamycin is famous for extending lifespan in animals, its common clinical use as an immunosuppressant for organ transplants has raised concerns about its safety as a longevity therapeutic. The researchers evaluated how a 5-month regimen of low-dose dietary rapamycin affects the immune system of aging mice under baseline conditions and during an acute inflammatory event.
Key Findings
1. No General Immunosuppression
The low-dose rapamycin treatment did not trigger widespread changes or broad suppression across the immune system:
- Myeloid Cells: It had no significant impact on the abundance of monocytes or neutrophils in the blood, bone marrow, spleen, or peritoneal cavity. The standard “myeloid skewing” (an overproduction of myeloid cells commonly seen in aging) was not altered.
- B Cells: B-cell populations and their development in the bone marrow remained steady, though there was a minor, non-significant trend toward rescuing younger levels of mature and transitional B cells.
- Brain Microglia: The resident immune cells of the brain (microglia) maintained a normal presence and baseline structure, proving the low dose didn’t compromise central nervous system safety.
2. Suppression of “Inflammaging” T Cells
The most targeted finding involved gamma delta ($\gamma\delta$) T cells, which produce Interleukin-17 (IL-17). IL-17 is a pro-inflammatory cytokine tightly linked to chronic, age-related tissue inflammation (often called inflammaging).
- Aging naturally causes a major accumulation of these IL-17-producing $\gamma\delta$ T cells, particularly in the peritoneal cavity.
- Long-term rapamycin treatment selectively restricted this expansion, blunting the age-associated spike in these specific pro-inflammatory cells.
3. Protection Against Neuroinflammation
To see how the treated immune system handles an active threat, the researchers introduced a peripheral bacterial mimic (an LPS challenge) to spark acute systemic inflammation.
- Lower Systemic Inflammation: Mice treated with rapamycin showed significantly lower levels of circulating IL-17 in the blood after the inflammatory challenge.
- Blunted Brain Inflammation: This drop in peripheral IL-17 strongly correlated with a reduction in the inflammatory behavior of brain microglia. Essentially, lowering peripheral IL-17 helped shield the brain from severe neuroinflammation during a systemic immune crisis.
The Takeaway
The study concludes that long-term, low-dose rapamycin exposure does not cause harmful, sweeping immunosuppression. Instead, it acts as a highly selective immunomodulator. By keeping IL-17-producing $\gamma\delta$ T cells in check, it tempers chronic age-related inflammation and offers a protective shield against severe neuroinflammation brought on by infection or systemic illness.